Covid-19 roundup: Gilead touts pre­clin­i­cal promise for oral remde­sivir; Roche pre­pares for virus to be­come en­dem­ic

4 years ago
Coronavirus

Five months af­ter get­ting slapped with a clin­i­cal hold, KalVista gets the OK to restart oral HAE pro­gram

4 years ago
FDA+

#ES­MO21 is loom­ing, and we have a great group of ex­perts lined up to help make sense of the news

4 years ago
Bioregnum
R&D

Ab­Cellera ac­quires trans­mem­brane pro­tein pro­duc­er; Com­pass gains psy­che­del­ic IP port­fo­lio

4 years ago
News Briefing

Ser­vices firm Mesa buys out mol­e­c­u­lar di­ag­nos­tics play­er for a cool $300M as ge­net­ics test­ing gains steam

4 years ago
Deals

Covid-19 roundup: Cure­Vac backs out of man­u­fac­tur­ing con­tracts as de­mand dwin­dles; De­spite PhII/III flop, biotech ...

4 years ago
Coronavirus

The team be­hind eF­FEC­TOR's SPAC deal is back af­ter go­ing from launch to merg­er in just 4 months

4 years ago
Financing

How Jan Skvar­ka and Tril­li­um went from down and out to buy­out with Pfiz­er

4 years ago
Deals

Ebo­la vac­cine built on same tech­nol­o­gy as Covid-19 jab from J&J shows long-last­ing suc­cess

4 years ago
R&D

Shang­hai biotech tack­ling kid­ney dis­ease gets an­oth­er round of cash

4 years ago
Financing

Bill Haney adds an­oth­er $133M to Sky­hawk's cof­fers, as the RNA start­up guns for the clin­ic

4 years ago
Financing

Spurred on by Or­biMed part­ner's di­ag­no­sis, Van­qua Bio takes aim at neu­rode­gen­er­a­tive dis­ease with blue-chip back­ers

4 years ago
Financing

Light­stone Ven­tures un­veils $375M third fund, this time ex­pand­ing its wish­list in blos­som­ing CNS field

4 years ago
Financing

Rosana Kapeller rais­es $77M in bid to make re­peatome drugs a re­al­i­ty

4 years ago
Financing

Fourth boy dies in Astel­las-Au­dentes gene ther­a­py tri­al, rais­ing fresh fears for the field

4 years ago
R&D
Cell/Gene Tx

Ger­man ra­dio­phar­ma forms an­oth­er Chi­na joint ven­ture; Urovan­t's Gemte­sa pass­es blood pres­sure study

4 years ago
News Briefing

Se­r­i­al en­tre­pre­neur Gary Glick sells an­oth­er one of his star­tups for $229M — this time to an un­like­ly buy­er

4 years ago
Deals

French biotech rais­es $75M for new cell ther­a­py man­u­fac­tur­ing tech, Parkin­son's treat­ment

4 years ago
Financing
Cell/Gene Tx

Five Prime founder Rusty Williams sets out to test the lim­its of cell ther­a­py with ax­olotl-in­spired biotech

4 years ago
People
Financing

Bel­lus says its Mer­ck cough ri­val passed a PhI­Ib test af­ter ear­li­er flop, but in­vestors can't make up their minds

4 years ago
R&D

Trans-Pa­cif­ic pow­er play­er Ever­est jumps on mR­NA vac­cine deal with Prov­i­dence, pay­ing $100M up­front to tap plat­form ...

4 years ago
Deals
China

Bris­tol My­ers rolls out 3-year mesothe­lioma da­ta for Op­di­vo/Yer­voy in first look at ES­MO slate

4 years ago
Pharma

Da­ta do not sup­port wide­spread Covid vac­cine boost­ers right now, out­go­ing FDA lead­ers write in the Lancet

4 years ago
FDA+
Coronavirus

Biotech's 'found­ing fa­ther' and in­flu­en­tial deal bro­ker Fred Frank dies at 89

4 years ago
People
First page Previous page 639640641642643644645 Next page Last page
A service from the Financial Times